RT Journal Article
SR Electronic
T1 A recurrent mutation at position 26,340 of SARS-CoV-2 is associated with failure of the E-gene qRT-PCR utilised in a commercial dual-target diagnostic assay
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.28.20083337
DO 10.1101/2020.04.28.20083337
A1 Artesi, Maria
A1 Bontems, Sébastien
A1 Göbbels, Paul
A1 Franckh, Marc
A1 Maes, Piet
A1 Boreux, Raphaël
A1 Meex, Cécile
A1 Melin, Pierrette
A1 Hayette, Marie-Pierre
A1 Bours, Vincent
A1 Durkin, Keith
YR 2020
UL http://medrxiv.org/content/early/2020/06/23/2020.04.28.20083337.abstract
AB Control of the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic requires accurate laboratory testing to identify infected individuals, while also clearing essential staff to continue work. At the current time a number of qRT-PCR assays have been developed to identify SARS-CoV-2, targeting multiple positions in the viral genome. While the mutation rate of SARS-CoV-2 is moderate, given the large number of transmission chains it is prudent to monitor circulating viruses for variants that might compromise these assays. Here we report the identification of a C-to-T transition at position 26,340 of the SARS-CoV-2 genome which is associated with failure of the cobas® SARS-CoV-2 E-gene qRT-PCR in eight patients. As the cobas® SARS-CoV-2 assay targets two positions in the genome, the individuals carrying this variant were still called as SARS-CoV-2 positive. Whole genome sequencing of SARS-CoV-2 showed all to carry closely related viruses. Examination of viral genomes deposited on GISAID showed this mutation has arisen independently at least four times. This work highlights the necessity of monitoring SARS-CoV-2 for the emergence of SNPs which might adversely affect RT-PCRs used in diagnostics. Additionally, it argues that two regions in SARS-CoV-2 should be targeted to avoid false negatives.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Region Wallonne project WALGEMED(convention n 1710180).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Comite d Ethique Hospitalo-Facultaire Universitaire de Liege (Reference number: CE 2020/137).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the viral genomes have been deposited at GISAID